atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today launched Invyxis, a new, wholly owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation mental health treatments. Invyxis will bring proven medicinal chemistry tools and comprehensive biological screening approaches to atai’s growing enterprise of drug discovery and design.
READ ARTICLE
Learn about cutting-edge science and gain life-enhancing insights.
News
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics…
News
Stephen Bardin to Join atai Life Sciences as CFO Designate
Stephen Bardin to Join atai Life Sciences as CFO Designate June 17, 2022 Stephen Bardin will join as CFO Designate…
Articles
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical…
News
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health…
Articles
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a…
Articles
atai Life Sciences to Host Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,…
Press Inquiries
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Headquartered in Berlin, with offices in New York and London, our vision is to heal mental health disorders so that everyone everywhere can live a more fulfilled life.
GET IN TOUCH